Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study

Journal of Crohn's and Colitis

Volumn 7, Issue 8, 2013, Pages 636-643

  Herrlinger, K R ^a,o   Diculescu, M ^b   Fellermann, K ^c   Hartmann, H ^d   Howaldt, S ^e   Nikolov, R ^f   Petrov, A ^g   Reindl, W ^h   Otte, J M ⁱ   Stoynov, S ^j   Strauch, U ^k   Sturm, A ^l   Voiosu, R ^m   Ammendola, A ⁿ   Dietrich, B ⁿ   Hentsch, B ⁿ   Stange, E F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Gastroenterologische Gemeinschaftspraxis   (Germany)

^e Gastroenterologische Schwerpunktpraxis   (Germany)

^f Clinic for Gastroenterology   (Bulgaria)

^g MHAT Tokuda Hospital Sofia   (Bulgaria)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ ST JOSEF HOSPITAL   (Germany)

^j Clinic for Gastroenterology Sofia   (Bulgaria)

^k UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m V Babes National Institute of Pathology   (Romania)

ⁿ 4SC AG   (Germany)

^o Internal Medicine I   (Germany)

more..

Author keywords

Clinical trial; Crohn's disease; IBD; Ulcerative colitis; Vidofludimus

Indexed keywords

AMOXICILLIN; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INTERLEUKIN 17; METHOTREXATE; PREDNISOLONE; SC 12267; UNCLASSIFIED DRUG; VIDOFLUDIMUS;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENTERITIS; FATIGUE; FEMALE; FOLLOW UP; GLUCOSURIA; HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LEUKOCYTURIA; LIMIT OF QUANTITATION; LITHOTRIPSY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; OPEN STUDY; PRIORITY JOURNAL; PYELONEPHRITIS; RELAPSE; REMISSION; RHINOPHARYNGITIS; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

CLINICAL TRIAL; CROHN'S DISEASE; IBD; ULCERATIVE COLITIS; VIDOFLUDIMUS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BIPHENYL COMPOUNDS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; DICARBOXYLIC ACIDS; ENZYME INHIBITORS; FECES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; METHOTREXATE; MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PREDNISOLONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84880035682     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.09.016     Document Type: Article

References (33)

1. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
2. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
3. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006, 24:319-330.
4. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
5. Travis S.P., Stange E.F., Lémann M., Oresland T., Bemelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008, 2:24-62.
6. Pearson D.C., May G.R., Fick G., Sutherland L.R. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000, (2):CD000067.
7. Sandborn W., Sutherland L., Pearson D., May G., Modigliani R., Prantera C. Azathioprine or mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000, (2):CD00045.
8. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
9. Alfadhli A.A., McDonald J.W., Feagan B.G. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005, (1):CD003459.
10. Patel V., Macdonald J.K., McDonald J.W., Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, (4):CD006884.
11. Fraser A.G., Morton D., McGovern D., Travis S., Jewell D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16(4):693-697.
12. Uhlen S., Belbouab R., Narebski K., Goulet O., Schmitz J., Cézard J.P., et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006, 12(11):1053-1057.
13. Din S., Dahele A., Fennel J., Aitken S., Shand A.G., Arnott I.D., et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008, 14(6):756-762.
14. Lémann M., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., Delchier J.C., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130(4):1054-1061.
15. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
16. Leban J., Kralik M., Mies J., Gassen M., Tentschert K., Baumgartner R. SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors. Bioorg Med Chem Lett 2005, 15(21):4854-4857.
17. Fitzpatrick L.R., Deml L., Hofmann C., Small J.S., Groeppel M., Hamm S., et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 2010, 16(10):1763-1777.
18. Fitzpatrick L.R., Small J.S., Ammendola A. Inhibition of IL-17 release by the novel anti-inflammatory drug vidofludimus involves attenuation of STAT-3 and NF-kappa B signaling pathways in murine splenocytes and hapten-induced colitis. Gastroenterology 2011, 140(5):S837.
19. Herrlinger C., Manger B., Burmester G., Alten R., Jeka S., Lazarevic M., et al. SC12267, a novel inhibitor of human DHODH, in the treatment of rheumatoid arthritis. Ann Rheum Dis June 11-14 2008, Eular, Paris.
20. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
21. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Gillies R., Hopkins M., et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975, 69(1):96-99.
22. Kirk A.P., Lennard-Jones J.E. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982, 284(6325):1291-1292.
23. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55(1):47-53.
24. Maté-Jiménez J., Hermida C., Cantero-Perona J., Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12(11):1227-1233.
25. Oren R., Arber N., Odes S., Moshkowitz M., Keter D., Pomeranz I., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110(5):1416-1421.
26. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110(5):353-356.
27. Baron T.H., Truss C.D., Elson C.O. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993, 38(10):1851-1856.
28. Cummings J.R., Herrlinger K.R., Travis S.P., Gorard D.A., McIntyre A.S., Jewell D.P. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21(4):385-389.
29. Armuzzi A., De Pascalis B., Lupascu A., Fedeli P., Leo D., Mentella M.C., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004, 8(5):231-233.
30. Gavalas E., Kountouras J., Stergiopoulos C., Zavos C., Gisakis D., Nikolaidis N., et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology 2007, 54(76):1074-1079.
31. Barreiro-de Acosta M., Lorenzo A., Mera J., Dominguez-Muñoz J.E. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009, 3(4):271-276.
32. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111:641-649.
33. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081-1085.